We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer…